Document:

Document

Exhibit 10.1
BEIGENE, LTD.

RESTATED AMENDMENT NO. 2 TO SHARE PURCHASE AGREEMENT
THIS RESTATED AMENDMENT NO. 2 (this “Amendment”) to the SHARE PURCHASE AGREEMENT, dated as of October 31, 2019, as amended on December 6, 2019 (the “Agreement”), is made and entered into as of September 24, 2020, by and among BeiGene, Ltd., an exempted company incorporated in the Cayman Islands (the “Company”), and Amgen Inc., a Delaware corporation (the “Investor”), and restates in its entirety the Amendment No. 2 to the Agreement dated March 17, 2020. Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Agreement.
RECITALS
WHEREAS, pursuant to the Agreement, the Investor purchased and subscribed for Two Hundred Six Million Six Hundred Thirty-Five Thousand Thirteen (206,635,013) Ordinary Shares in the form of Fifteen Million Eight Hundred Ninety-Five Thousand One (15,895,001) American Depositary Shares of the Company at a purchase price of $13.45 per share, or $174.85 per American Depositary Share, at the Closing, which represented approximately twenty point five percent (20.5%) of the Company’s outstanding share capital as of that date and, pursuant to the Agreement, subsequent to the Closing, the Investor has purchased additional American Depositary Shares of the Company to account for dilution and maintain the Investor’s ownership interest;
WHEREAS, in order to continue to account for periodic dilution from the issuance of the Company’s shares under its equity incentive plans, the Company and the Investor would like to provide for the option to purchase by the Investor of such supplemental amount of American Depositary Shares of the Company on a monthly basis such that the Investor will hold approximately twenty point six percent (20.6%) of the Company’s outstanding share capital immediately following each such purchase in support of the maintenance of the Investor’s equity method accounting treatment for its investment in the Company;
WHEREAS, pursuant to Section 8.9 of the Agreement, no provision in the Agreement may be supplemented, deleted or amended except in a writing executed by an authorized representative of each of the Investor and the Company; and
WHEREAS, the Company will seek all approvals of the Company’s shareholders required for the Company to (i) enter into this Amendment and (ii) issue the Monthly Firm Shares (as defined below), in each case in accordance with the HK Listing Rules.
NOW, THEREFORE, in consideration of the foregoing and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereby agree as follows:
1.Addition of Section 2.4. The following shall be inserted as a new Section 2.4 of the Agreement:
“2.4 Monthly Sale of Additional Shares. 
(a)    Subject to the Subsequent Shareholder Approval and the Annual Shareholder Approvals, purchases and sales under this Section 2.4 shall commence on the first (1st) day of the month following the Subsequent Shareholder Approval (or if the Company’s American Depositary Shares are not trading on NASDAQ on such day, the next trading day) (the “Commencement Date”) and shall continue until the earliest of (i) the date on which the Investor and its Affiliates collectively own less than twenty percent (20%) of the outstanding share capital of the Company as a result of the Investor’s sale of 
1

Shares, (ii) written notice from either the Investor or the Company that such party wishes to terminate such monthly purchases and sales, which notice shall be provided at least sixty (60) days in advance of the termination of such monthly purchases and sales or, if requested by the Investor, such longer period as reasonably required, upon advice of Investor’s counsel, to permit the Investor to commence market purchases under a trading plan in accordance with Rule 10b5-1 under the Exchange Act, and (iii) the third anniversary of the Commencement Date (the “Monthly Sale Period”). Upon mutual agreement by the parties and subject to approval by the Company’s shareholders if required by the HK Listing Rules, this Amendment shall be extended for additional three-year terms upon expiration of the then current term.

(b)    During the Monthly Sale Period, on the first (1st) day of each month (or if the Company’s American Depositary Shares are not trading on NASDAQ on such day, the next trading day), the Company shall send or cause to be sent via e-mail to the Investor the following information (such  notice, the “Monthly Firm Shares Notice”): (i) the number of ADSs Outstanding and number of Non-Equity Incentive Shares, each as of the applicable Reference Date, (ii) the Amgen Holding and Amgen Percentage as of such Reference Date based on the latest information provided by the Investor (which shall be confirmed by the Investor and revised if inaccurate), (iii) the volume weighted average price of one Company American Depositary Share on NASDAQ for the ninety (90) calendar days preceding such Reference Date, as reported by Bloomberg (each, a “Monthly Firm Shares Purchase Price”) and (iv) an updated Company Disclosure Schedule as of the applicable Reference Date in accordance with Section 2.4(d), if any.  If the Amgen Percentage is less than the Trigger Percentage as of such Reference Date, then, upon the Investor’s written request (the “Investor Request”) delivered within two (2) Business Days following Investor’s receipt of the Monthly Firm Shares Notice, the Company hereby agrees to sell to the Investor and the Investor agrees to subscribe for such additional number of Ordinary Shares in the form of American Depositary Shares (the “Monthly Firm Shares”) calculated pursuant to the following formula:
X = (((A-B)*C) -D) / (1-C)
X = the number of Monthly Firm Shares expressed in ADSs
A = the number of ADSs Outstanding
B = the number of Non-Equity Incentive Shares
C = 20.6%
D = the Amgen Holding,

at a purchase price per Monthly Firm Share equal to the Monthly Firm Shares Purchase Price; provided, however, that in no event shall the aggregate number of Monthly Firm Shares issued during the Monthly Sale Period, exceed Seventy-Five Million (75,000,000) Ordinary Shares (subject to appropriate adjustment in the event of any share dividend, share split, combination or other similar recapitalization with respect to the Ordinary Shares).  If the Amgen Percentage in any such Monthly Firm Shares Notice is equal to or greater than the Trigger Percentage, then the Investor shall not have the option to subscribe for, and the Company shall not issue, any Monthly Firm Shares for such month.  The Monthly Firm Shares shall be in the form of American Depositary Shares, unless the Investor requests in writing that the Monthly Firm Shares be delivered in the form of Ordinary Shares, in which case the number of shares and purchase price shall be adjusted accordingly based on the ADS to Ordinary Share ratio.  Any Monthly Firm Shares purchased hereunder shall be “Shares” or “Deposit Shares” as the context shall so require for purposes of Article 1, Article 3, Article 4, Article 5 and Article 8 of the Agreement.  Until such time as the Investor elects to cease equity method accounting for its investment in the Company, subject to the Annual Shareholder Approvals, the Investor and Company acknowledge and agree that the Investor’s direct purchase of Ordinary Shares in the form of American Depositary Shares from the Company on a monthly basis hereunder shall be the primary means for the Investor to purchase shares in order to maintain such equity method accounting treatment.

2

(c)    Subject to the terms and conditions hereof, the closing of the purchase and sale of Monthly Firm Shares, if any, shall take place each month within seven (7) Business Days following the Reference Date, or at such other time as mutually agreed by the Company and the Investor (the “Monthly Closing”). At each Monthly Closing, the Company will instruct the Transfer Agent to deliver to the Investor, via book entry to the applicable balance account registered in the name of the Investor, the Monthly Firm Shares for such month, against payment of the aggregate Monthly Firm Share Purchase Price for such Monthly Firm Shares in U.S. dollars by wire transfer of immediately available funds to the order of the Company. 

(d)    For purposes of Article 3 and Article 4 of the Agreement, the representations and warranties contained therein shall be deemed made as of the date of the applicable Monthly Closing, as supplemented by, in the case of Article 3, (i) the Company’s most recent Form 10-K (including any information incorporated by reference therein from the Company’s definitive proxy statement on Schedule 14A) and any subsequent Form 10-Q and Form 8-K filed with or furnished to the SEC and made publicly available prior to the date of delivery of the Monthly Firm Shares Notice (other than (x) any information that is contained in the “Risk Factors” or “Note Regarding Forward-Looking Statements” or similar sections of such Company SEC Documents and (y) any forward-looking statements, or other statements that are similarly predictive or forward-looking in nature, contained in such Company SEC Documents), and (ii) any update to the Company Disclosure Schedule as of the applicable Reference Date provided by the Company to Investor in accordance with Section 2.4(b); provided that the Company shall not be required to provide any updates to (x) Section 3.2 (Subsidiaries) to list any newly formed subsidiaries since the most recent disclosures in the Form 10-K or any Form 10-Q, or (y) Section 3.3 (Capitalization) other than providing the updated number of outstanding shares included in the Monthly Firm Shares Notice, which shall constitute a representation and warranty of the Company under the Agreement as to such number of outstanding shares; and provided, further, that if there are any material updates to the Company Disclosure Schedule following delivery of the Investor Request, the Investor Request may be revoked prior to the issuance of the shares in the Investor’s sole discretion.
(e)    For purposes of this Section 2.4:
(i)    “ADS” means American Depositary Shares.
(ii)    “ADSs Outstanding” means the total number of the Company’s Ordinary Shares outstanding prior to NASDAQ market opening on the Reference Date, expressed in terms of ADSs.
(iii)    “Amgen Holding” means the number of the ADSs Outstanding held by the Investor as of the latest Reference Date.
(iv)    “Amgen Percentage” means the percentage of the ADSs Outstanding held by the Investor as of the latest Reference Date.
(v)    “Annual Shareholder Approvals” means, following the Subsequent Shareholder Approval, the annual approvals of the Company’s shareholders required for the Company to continue issuing the Monthly Firm Shares during the term of this Agreement in accordance with the conditions of the waiver granted by The Stock Exchange of Hong Kong Limited (the “HK Stock Exchange”) on August 10, 2020 from the requirements of Rules 13.36(1)(a) and 14A.36 of the HK Listing Rules.
(vi)    “Non-Equity Incentive Shares” means the aggregate number of shares issued other than upon exercise, vesting or issuance of share options, restricted shares, restricted share units, Ordinary Shares or ADSs, or other equity incentives to employees, consultants and directors of the Company since the Commencement Date, expressed in terms of ADSs; provided, however, that (x) if the Investor exercised its participation right pursuant to Section 5.16(a) in whole or in part in an offering (subject to applicable Law, HK Listing Rules and any waiver therefrom granted by the HK Stock 
3

Exchange) or (y) if the Investor purchased Ordinary Shares (expressed in terms of ADSs) or ADSs through a trading plan in accordance with Rule 10b5-1 under the Exchange Act or otherwise purchased Ordinary Shares (expressed in terms of ADSs) or ADSs from any Person other than the Company, then such shares issued in such Non-Equity Incentive Share offering(s) shall not be deemed as Non-Equity Incentive Shares to the extent Investor’s purchases pursuant to clauses (x) and (y) were made in response to the pro rata dilution to the Investor from such Non-Equity Incentive Share offerings.

(vii)    “Reference Date” means the day on which the Company’s ADSs are trading on NASDAQ immediately preceding the first (1st) day of each calendar month during the Monthly Sale Period.
(viii)    “Subsequent Shareholder Approval” means the approval of the Company’s shareholders required for the Company to (i) enter into Restated Amendment No. 2 to the Share Purchase Agreement and (ii) issue the Monthly Firm Shares in accordance with the HK Listing Rules.
(ix)    “Trigger Percentage” means 20.4% of the Company’s outstanding share capital (expressed in terms of ADSs).”
2.Amendment to Section 5.16(a). The first sentence of Section 5.16(a) is deleted in its entirety and replaced with:
“If the Company proposes to offer or sell any Ordinary Shares, American Depositary Shares or Ordinary Share Equivalents after the Closing Date, other than pursuant to the Plans (“New Securities”), and at the time immediately prior to such offer or sale the Investor holds no more than twenty one percent (21.0%) of the Company’s outstanding share capital, the Company shall use reasonable best efforts to provide the Investor with an opportunity to participate in such offering or sale and purchase upon the same terms and conditions as other purchasers in the offering or sale of the New Securities, up to that portion of such New Securities as is necessary to allow the Investor to hold approximately twenty point six percent (20.6%) of the Company’s share capital after the sale of New Securities, so long as the Investor’s ownership percentage prior to such sale has not decreased as a result of the Investor’s sale of Shares or the Investor’s failure to participate in future offerings or sales of New Securities in which Investor is given the opportunity to participate pursuant to this Section 5.16(a), subject to applicable Law, HK Listing Rules and any waiver therefrom granted by the HK Stock Exchange.”
3.Addition of Section 5.21. The following shall be inserted as a new Section 5.21 of the Agreement:
“5.21 Preparation of Proxy; Shareholders Meeting; Board Recommendation.

(a)     As promptly as reasonably practicable after the execution of this Amendment, the Company shall prepare and cause to be filed with the SEC and the HK Stock Exchange a proxy circular relating to the Subsequent Shareholder Approval (such proxy circular, and any amendments or supplements thereto, the “Supplemental Proxy Statement”). The Investor shall assist and cooperate with the Company in the preparation of the Supplemental Proxy Statement and the resolution of any comments to the Supplemental Proxy Statement received from the SEC or HK Stock Exchange. The Company shall promptly correct any information in the Supplemental Proxy Statement if and to the extent such information becomes false or misleading in any material respect. The Company shall notify the Investor upon the receipt of any comments from the SEC or HK Stock Exchange, as applicable, and of any request by the SEC or HK Stock Exchange, as applicable, for amendments or supplements to the Supplemental Proxy Statement. The Company shall use its reasonable best efforts to (i) respond as promptly as reasonably practicable to any comments received from the SEC or HK Stock Exchange, as applicable, concerning the Supplemental Proxy Statement and to resolve such comments with the SEC or HK Stock Exchange, as applicable, and (ii) to cause the Supplemental Proxy Statement to be disseminated to its shareholders as promptly as reasonably practicable after the resolution of any such comments.
4

(b)     The Company shall take all necessary actions in accordance with applicable Law, the governing documents of the Company and the rules of NASDAQ and the HK Stock Exchange, as applicable, to duly call, give notice of, convene and hold a special shareholders meeting (the “Supplemental Meeting”) for the purpose of obtaining the Subsequent Shareholder Approval, as soon as reasonably practicable after the SEC or HK Stock Exchange, as applicable, confirms that it has no further comments on the Supplemental Proxy Statement. Notwithstanding any provision of this Agreement to the contrary, the Company may adjourn, recess or postpone the Supplemental Meeting (i) to the extent necessary to ensure that any required supplement or amendment to the Supplemental Proxy Statement is provided to the shareholders of the Company within a reasonable amount of time in advance of the Supplemental Meeting, (ii) if as of the time for which the Supplemental Meeting is originally scheduled (as set forth in the Supplemental Proxy Statement) there are insufficient shares of capital stock of the Company represented (either in person or by proxy) to constitute a quorum necessary to conduct the business of the Supplemental Meeting or (iii) as may be required by applicable Law.”

4.General
A.    Except as expressly modified by this Amendment, the terms and provisions of the Agreement shall remain unchanged and in full force and effect in accordance with its terms.
B.    Each of the parties hereto shall bear its respective costs, including legal fees, and expenses incurred in connection with the preparation of this Amendment and the activities incurred in connection therewith.
C.    This Amendment may be executed in one or more counterparts, each of which shall be deemed to be an original but all of which shall constitute one and the same agreement.
D.    This Amendment shall be governed by and construed in accordance with the Laws of the State of New York, without regard to the conflict of laws principles thereof that would require the application of the Law of any other jurisdiction.
E.    The Agreement and this Amendment constitute the full and entire understanding and agreement between the Company and the Investor with regard to the subject matter hereof and neither the Company nor the Investor shall be liable or bound to any other in any manner by any representations, warranties, covenants and agreements except as specifically set forth herein and therein.

F.    This Amendment shall become effective immediately upon execution by the Company and the Investor.
[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

5

IN WITNESS WHEREOF, the parties have executed this Amendment as of the date first written above.
THE COMPANY:
BEIGENE, LTD.
By:  /s/ Scott A. Samuels    
Name:    Scott A. Samuels
Title:    Senior Vice President, General Counsel

6

IN WITNESS WHEREOF, the parties have executed this Amendment as of the date first written above.
INVESTOR:
AMGEN INC.
By:  /s/ Robert A. Bradway    
Name:    Robert A. Bradway
Title:    Chairman of the Board, President & CEO

7EX-10.1

 Exhibit 10.1 
  

 

											
	  	  	Percentage	 	  	  

Annual Amount
(USD)
	 	  	  
				
	   Base Annualised Salary
	  	 	 	 	  	$	700,000	 	  	 plus superannuation up to the  

maximum contribution base  
  

				
	   Potential Performance Bonus
	  	 	 	 	  	 	 	 	  	 
				
	   Short Term Incentive Plan
	  	 	100%	 	  	$	700,000	 	  	 
				
	   Long Term Incentive Plan
	  	 	140%	 	  	$	980,000	 	  	 
				
	   Total Potential Remuneration
	  	 	 	 	  	$	2,380,000	 	  	 plus superannuation up to the  

maximum contribution base  
  

	
	   For an explanation of the above terms and payment conditions, see the rest of this
Contract.

 The following documents apply to the offer of employment made by Peabody Energy Australia Coal Pty Ltd
(the Company) to you: 
 (a)        General Conditions document (General
Conditions); 
 (b)        Schedule 1 - Employment Offer Term Sheet (Employment Offer Term
Sheet); 
 (c)        Schedule 2 - Chief Operating Officer Job Description (Job
Description) 
 (d)        Schedule 3 - 2019 Executive Severance Plan (including without
limitation the Participation Agreement in Exhibit A) (2019 Executive Severance Plan); 
 (collectively referred to as the
Contract) 
 Any ambiguity or discrepancy between the documents set out above is to be resolved and interpreted according to
the same order of precedence as the documents are listed, with the documents higher in the list having higher priority. 
 If you
accept the Contract, while you are not formally a participant in the 2019 Executive Severance Plan (the Severance Plan) with Peabody Energy Corporation and have not formally entered into a Participation Agreement pursuant to the Severance
Plan, you acknowledge that you are required to comply with the terms of the Severance Plan and Participation Agreement during your employment with the Company as set out in this Contract, and that you will be entitled to the benefits set forth in
the Severance Plan upon certain terminations of your employment, subject to your satisfaction of the requirements set forth in the Severance Plan and Participation Agreement. 
  

 

  

  
      

    Page 1 
  

  
  
 

         
  

     

  

      

  

 GENERAL CONDITIONS 

 
 COMMENCEMENT DATE 

 
 Your commencement date will be as agreed, or, in the absence of
agreement, a date set by the Company. 
 PRE-EMPLOYMENT CONDITIONS 

 
 Background checks 

It is a condition of your employment that you satisfy a number of background checks, which shall be reviewed at the Company’s sole and absolute discretion,
including but not limited to: 
  

	a)	 reference checks; 

  

	b)	 verification of your academic qualifications (by providing the Company with an original academic transcript or other
evidence satisfactory to the Company); 

  

	c)	 drug test 

  

	d)	 criminal record check; and 

  

	e)	 proof of your eligibility to lawfully work in Australia. 

You warrant that any information that you have provided to the Company in relation to the above matters is true and correct. If you have already commenced employment
with the Company and the results of any background checks are unsatisfactory to the Company or inconsistent with the warranty you have given, the Company may terminate your employment without notice. 

Right to work in Australia 
 The commencement and
continuation of your employment with the Company is subject to you acquiring and maintaining all necessary approvals to lawfully enter, live and work in Australia. If required, the Company may provide you with reasonable assistance in that regard,
including the payment of your reasonable costs of lawfully securing and maintaining required approvals. You must provide to the Company and/or the Department of Home Affairs, all relevant documentary evidence that is required by either or both of
them, within the timeframes specified by them. 
 HEALTH AND SAFETY REQUIREMENTS 

 
 Medical 

Your ongoing employment will be subject to maintaining your health and fitness at a level relevant to your role and work requirements. You may be required to undergo
periodic medical examinations to monitor your fitness for work. 

  

 

     

 

  

 

 

  

  

      

Page 2 

  
  
 

         
  

     

  

      

  

 Consent to Drug and Alcohol Testing 

Upon entering into this Contract, a condition of your employment is that you agree and consent to undergo drug, alcohol and substance abuse testing as required by the
Company in accordance with our policies and procedures, as amended from time to time. 
 Safety 

The Company will provide equipment and facilities it considers necessary for you to perform your duties safely. In performing your duties you are required to work in a
manner that will not injure or put at risk yourself, fellow employees or any other person on site. You will be required to attend an induction course prior to commencing work on a site. You are required to wear and use accident prevention equipment
and protective clothing supplied by the Company for the purpose for which it is supplied, at all times whilst on site. Should you be required to drive motor vehicles to execute your duties, you must maintain a current licence appropriate for the
class of vehicle. You must immediately notify your Manager of expiry, restrictions or loss of licence. 
 EMPLOYMENT TYPE AND HOURS OF WORK

  
 You will be employed as a full-time permanent
employee subject to termination of employment in accordance with the terms of this Contract. Your ordinary hours of work will be 38 hours per week plus reasonable additional overtime. 

Peabody Energy’s subsidiaries, affiliates and customers span the globe. Peabody Energy’s global headquarters and certain departments and operations with whom
you will regularly interact have time zones that are different from Brisbane, Australia. Circumstances -will routinely require you to work outside normal hours including on weekends and public holidays to ensure the full requirements of your
position are met. Your remuneration package has been developed to account for this and is inclusive of all amounts payable for all hours worked. The Company reserves the right to vary these work arrangements as business requirements dictate. 

WORK LOCATION 
  

Whilst you will be initially based in Brisbane, Australia, this role is a US based position and you are required to spend up to 50% of your time working in St Louis,
Missouri. You and the Company agree that you will seek an essential business exemption to allow you to travel to the US to perform your duties as necessary, and that your ability to meet these requirements is subject to securing that exemption. 

Additionally, you may be required to travel as part of your duties and work at places other than Brisbane or St Louis, for short periods of time. Any ad hoc travel, and
associated costs, connected with your employment will be paid for by the Company. You also acknowledge that your workplace may change during the course of your employment at the reasonable direction of the Company. 

  

 

     

 

  

 

 

  

  

      

Page 3 

  
  
 

         
  

     

  

      

  

 RELOCATION TO UNITED STATES OF AMERICA AND SUBSEQUENT EMPLOYMENT 

 
 Requirement to relocate 

You agree that you will relocate to the Company’s headquarters in St. Louis, Missouri, USA at the earliest opportunity, but not later than 12 April 2022. 

The Company will provide support and assistance, including legal counsel of the Company’s choice, to obtain the relevant employment authorization and work visa,
along with appropriate visas for an accompanying spouse and for dependent children under the age of 26. Upon relocation to the US, you will become an employee of the US entity. For the avoidance of doubt, your relocation to the US will be a local
assignment and not an expatriate assignment. 
 You will be provided with relocation benefits in accordance with the Company’s then-applicable relocation
practices. 
 Termination of Contract and Relocation 

This Contract will terminate and have no further force or effect at the earlier of your relocation to St Louis, Missouri or 12 April 2022. 

Upon relocation to the USA, Peabody Investments Corporation (PIC) intends to offer you employment in accordance with applicable law in the USA and subject to the
relevant aspects of the Employment Offer Term Sheet located at Schedule 1 and the 2019 Executive Severance Plan located at Schedule 3 to this Contract. 
 Failure to Relocate 
 If you decide that you will not be relocating to the US, you must provide the Company with 90 days’ written
notice prior to 12 April 2022. 
 If you do not relocate to St Louis, Missouri by 12 April 2022, this Contract and your employment will automatically
terminate on that date without a requirement for either party to provide notice to the other. 
 Notwithstanding any other provision in this Contract, if you fail to
relocate to the US by 12 April 2022, you will not be entitled to any termination payments, including under the 2019 Executive Severance Plan upon your termination of employment. 

REMUNERATION AND EXPENSES 

 
 Remuneration 

Your remuneration has been structured to include all factors associated with this appointment, including but not limited to hours of work and other allowances and
conditions and is paid in satisfaction of any entitlements to 

  

 

     

 

  

 

 

  

  

      

Page 4 

  
  
 

         
  

     

  

      

  

 remuneration that you have under any Australian law. Your salary will be paid in AUD in monthly instalments into your
nominated bank account on approximately the 15th day of each month. In order to facilitate payment in AUD, your salary will be converted from USD to AUD on a one-time basis, determined as of the commencement
date of your employment with the Company based on the trailing 90-day average of USD to AUD conversion rates as published on the website of the Reserve Bank of Australia (www.rba.gov.au) (the Agreed Conversion Rate). Your salary will remain fixed at that rate unless there is a change in base salary in the
normal course of employment and subject to Compensation Committee approval. 
 Your total remuneration package is reviewed annually at the Company’s
discretion and is subject to approval by the Compensation Committee of the Peabody Energy Corporation (PEC) Board of Directors (the Compensation Committee). If you join the Company between 1 October and 31 December of the
year you will not be eligible for the following year’s salary review effective 1 April. 
 Expenses 

The Company, upon submission of a personal expense claim, will reimburse any reasonable costs incurred in regard to work-related expenses. 

SUPERANNUATION 
  

The Company will make monthly contributions (currently at the rate of 9.5% of your Base Annualised Salary) in accordance with legislative requirements up to the maximum
superannuation contribution base. Salary sacrifice options are available to you should you wish to make additional contributions, these will be in accordance with the applicable company policy as amended from time to time and Australian taxation
legislation. 
 SIGNING BONUS 

 
 You will receive a
one-time signing bonus in the amount of US$600,000.00 (less any applicable taxation) within 30 days of you first commencing employment with the Company. The signing bonus will be paid to you in AUD at the
Agreed Conversion Rate. 
 You agree to repay the full US$600,000.00 (without deduction, and regardless of the currency exchange rate in effect at that time) to the
Company in the event that you resign from your employment or are terminated for cause within one year of commencing employment with the Company. 
 PERFORMANCE BONUS 
  
 In
addition to your Base Annualised Salary, you will be entitled to participate in the Peabody short term incentive plan (STIP) and the long-term incentive plan (LTIP). The STIP and LTIP may be changed at the discretion of the Company,
subject to approval by the Compensation Committee. 

  

 

     

 

  

 

 

  

  

      

Page 5 

  
  
 

         
  

     

  

      

  

 For 2020, you will be entitled to receive a pro-rata portion of the Short Term
Incentive, subject to performance metrics and/or objectives as recommended by the Chief Executive Officer and subject to approval of the Compensation Committee of the Board of Directors. 

Beginning 1 January 2021, you will be entitled to participate in the STIP and LTIP on the same terms and conditions as other members of the Company’s
Executive Leadership Team. 
 Any Incentive payment: 
  

	a)	 is calculated upon a combination of key measures of the Company’s performance and your assessed performance against
key performance indicators that will be developed annually for the particular plan; 

  

	b)	 is paid in March of the following year; and 

 

	c)	 is only payable to employees employed at the time the payment is made. 

DEDUCTION FROM EMPLOYEE’S PAYMENTS 

 
 As permitted by law, the Company, after advising you, may make
deductions from your pay or leave entitlement in the event of: 
  

	a)	 overpayment by the Company; 

  

	b)	 your failure to provide notice of resignation as provided by this Contract; 

 

	c)	 any unauthorised absence or default; 

 

	d)	 you owing any debt to the Company, including any unauthorised expenditure incurred by yourself on behalf of the Company;

  

	e)	 outstanding payments incurred under Salary Sacrifice arrangements; or 

 

	f)	 agreement between the Company and yourself over specific deduction(s). 

If a further written authority to deduct monies from salary or wages is required by law to make a deduction authorised by this clause, you undertake to provide this
authority. 
 2019 EXECUTIVE SEVERANCE PLAN 

 
 The provisions of the 2019 Executive Severance Plan and the
Participation Agreement pursuant to the 2019 Executive Severance Plan regarding termination of employment, confidentiality and restraints of trade apply to you during your employment with the Company (without limiting any other obligations and
benefits that you have under the other terms of that document). The obligations owed by you under the provisions of the 2019 Executive Severance Plan and the Participation Agreement regarding confidentiality and restraints of trade continue to apply
after the cessation of your employment with the Company. 
 In the event of a conflict between the 2019 Executive Severance Plan and the Participation Agreement and
the General Conditions, the General Conditions prevail. 

  

 

     

 

  

 

 

  

  

      

Page 6 

  
  
 

         
  

     

  

      

  

 The Company will obtain approval of the Company’s shareholder in accordance with the Corporations Act 2001 (Cth)
in the event you become entitled to payments under the 2019 Executive Severance Plan. 
 DIRECTORSHIPS     

  
 At the discretion of the Board, and in
accordance with the PEC Corporate Governance Guidelines, you may be invited to continue your service on the PEC board of directors. While serving as an executive officer and Director, you will not receive any additional remuneration. 

You may continue on the WorkPac Board while employed by the Company and we consent to you continuing to hold this position (subject to compliance with PEC policies and
all applicable laws, rules and regulations). You agree to resign from the EMECO board by no later than 31 January 2021. Only one non-Peabody Energy Corporation directorship is allowed, and any new
directorships must be approved in advance by the President & CEO. 
 COMPANY POLICIES AND PROCEDURES 

 
 The Company, its parent company and associated entities have
developed policies and procedures to assist in the effective management of the business. These policies and procedures, including any which are specifically referenced in this Contract, are not intended to be legally binding on the Company and do
not form part of the terms and conditions of this Contract. 
 The policies or procedures may be modified, replaced or withdrawn at any time. You must familiarise
yourself with all current policies and procedures. 
 Unless otherwise directed by the Company, you are required to act in conformity with the policies and procedures
in effect at the relevant time. Compliance with the policies and procedures creates no right or entitlement to any benefits or conditions outside the terms and conditions of this Contract. 

CODE OF BUSINESS CONDUCT AND ETHICS 

 
 The Peabody Code of Business Conduct and Ethics (as amended from
time to time) will be read in conjunction with these conditions of employment and signed in acceptance. Breaches of the Peabody Code of Business Conduct and Ethics will be investigated and subject to findings, disciplinary action up to and including
termination of employment may be taken. 
 CONFLICTS OF INTEREST 

 
 Gratuities 

You must not accept from any person or company, any payment or benefit in any form whatsoever, which would constitute a conflict of interest with your employment with
the Company. 

  

 

     

 

  

 

 

  

  

      

Page 7 

  
  
 

         
  

     

  

      

  

 Exclusive Service 

Except as explicitly set forth herein, you will not, without the prior written consent of the Company, in any capacity, during or outside of work time, directly or
indirectly be engaged in or have any other interest (whether for financial advantage or not) which: 
  

	a)	 competes with, conflicts with, or detracts from any business of the Company, its parent company, or any associated
entity; or 

  

	b)	 interferes or conflicts with the proper discharge of your duties and/or obligations to the Company, its parent company,
or any associated entity. 

 COMPANY PROPERTY 

 
 Company property may only be used in the legitimate performance
of your duties under this Contract. When your employment ends, or if requested by the Company during your employment, you will immediately deliver to the Company: 
  

	a)	 all originals and copies in any form (including but not limited to computer data) of all books, records and documents
relating to your duties, functions and responsibilities as an employee of the Company or its business affairs (including client details); and 

  

	b)	 all other things belonging to the Company (including but not limited to keys, security cards and passes, mobile phones,
copies of documents and computerised information) which you have in your possession or which has otherwise been provided to you during your employment. 

INTELLECTUAL PROPERTY AND MORAL RIGHTS 

 
 You: 

 

	a)	 agree to assign to the Company all existing and future intellectual property rights in all articles, documents,
inventions, models, designs, drawings, plans, software, reports, proposals, processes and other materials conceived, created or generated by you in the course of your employment with the Company (whether alone or with the Company, its other
employees or contractors and whether during or outside working hours): 

  

	 	(i)	 using the Company’s or any of its clients’ premises, resources or facilities; 

 

	 	(ii)	 in the course of, as a consequence of or in relation to the performance of your duties; 

 

	 	(iii)	 directly or indirectly as a result of your or anybody else’s access to the Confidential Information (as defined in
the 2019 Executive Severance Plan); 

  

	 	(iv)	 in respect of or associated with any of the Company’s products or services and any alterations or additions or
methods of making, using, marketing, selling or providing these products or services; or 

  

	 	(v)	 relating to other intellectual property of the Company or any Group Companies; and 

 

	b)	 acknowledge that by virtue of this clause all such existing rights are vested in the Company and, on their creation, all
such future rights will vest in the Company. 

 You agree to do all things reasonably requested by the Company to enable the Company to further
assure the rights assigned under the above clauses. 

  

 

     

 

  

 

 

  

  

      

Page 8 

  
  
 

         
  

     

  

      

  

 You may have Moral Rights in works which you may in the future create in the course of your employment with the
Company. By signing this Contract, you voluntarily and unconditionally consent to all or any acts or omissions by the Company or persons authorised by the Company in relation to any and all works made or to be made by you (whether before or after
this consent is given) during your employment with the Company which would otherwise infringe your Moral Rights. You acknowledge that your consent is given voluntarily and without reliance on any statement or representation made by the Company or
anyone acting on behalf of the Company. 
 “Moral Rights” means the right of attribution of authorship, the right to prevent false attribution of
authorship, and the right of integrity of authorship (as defined in the Copyright Act 1968 ( Cth)). 
 PRIVACY STATEMENT, IDENTIFICATION AND
SURVEILLANCE 
  
 Privacy
Statement 
 Certain personal information is collected by the Company about you that is necessary for the Company to effectively manage your employment.
This information may be disclosed to third parties or related companies of the Company where it is directly related to your employment. The information that you provide will not be disclosed to any other organisations or individuals unless required
or authorised by law, or unless you consent to this disclosure. During the course of your employment, photographs of you may be taken and used for advertising / promotional purposes. 

Identification 
 You consent to the Company
photographing you for identification purpose to help provide a safe and secure working environment for you and others and for Human Resources and other related business purposes. 

Surveillance 
 As part of the Company’s duty
of care and as a condition of using the Company’s communication and technology systems, you acknowledge that the Company may conduct the following surveillance: 

a)        continuous and ongoing monitoring, recording and surveillance, from the commencement of your employment, of all
communications and use of information technology systems and electronic resources in the course of your employment and when using resources of the Company outside work; and 

b)        continuous and ongoing camera (video) surveillance from the commencement of your employment in areas of the workplace
in which you may be recorded. 
 LEAVE ENTITLEMENTS AND PUBLIC HOLIDAYS 

 
 Leave entitlements available to you under this Contract will
satisfy the Company’s obligations under the National Employment Standards (NES), the Fair Work Act 2009 ( Cth) and any other applicable legislation. 
 Annual Leave 
 Annual leave will be 4 weeks’ leave, for each 12 months of continuous service, which will accrue on a pro rata
basis. 

  

 

     

 

  

 

 

  

  

      

Page 9 

  
  
 

         
  

     

  

      

  

 Annual leave will be paid at your Base Annualised Salary. You may apply for and take annual leave at any time,
provided the leave is taken at a time convenient and approved by your Manager, taking into account Company staffing requirements. 
 You may be required to take
annual leave, as directed by the Company. It is Company policy that annual leave entitlements should not accrue beyond 8 weeks accumulated entitlement. On termination of employment you will be paid any accrued untaken annual leave entitlements. 

You may be entitled, by agreement with the Company, to cash out a portion of your annual leave accrued, provided the cashing out results in the remaining accrual being
4 weeks or more. 
 Long Service Leave 

Brisbane based employees will accrue long service leave at the rate of 8.6667 weeks for each 10 years of continuous service. Leave is payable at your Base Annualised
Salary and in accordance with applicable state legislation. 
 Personal/Carer’s Leave 

You are entitled to up to 10 days paid leave, calculated according to your work roster, for absences taken for the purpose of Personal leave or Carer’s leave. 

●        Personal leave refers to leave taken because of an illness or
medical condition; 
 ●        Carer’s leave is leave taken to
provide care or support to a member of your immediate family or household due to personal illness or injury or an unexpected emergency. 
 Personal/Carer’s leave
will be paid at your Base Annualised Salary. You must inform the Company, wherever practicable, prior to the commencement of such absence, of the nature of the illness and the estimated duration of the absence. Company policy will inform you whether
you are required to provide a doctor’s certificate or other supporting documentation. 
 Personal/Carers leave will accrue on a pro rata basis at the rate of 10
days for each 12 months of continuous service, calculated according to your work roster. Your Personal/Carers leave balance is reduced by any Personal/Carers leave that you take throughout your employment with the Company. 

Additional Personal Leave Benefit 
 After the
first 12 months of employment, in the event that you are unable to attend work for reasons of genuine sickness or injury and you do not have accrued but untaken personal leave to cover the full period of the absence, the Company in its absolute
discretion may continue to pay you your salary for a period of up to 6 months from the first day of your absence from work. 
 Maintenance of this benefit is entirely
at the discretion of the Company. You are also required to reasonably cooperate with the Company in relation to the management of your rehabilitation, including: 
  

	 	a)	 Providing up to date information to the Company in relation to the progress of your illness or injury;

  

 

     

 

  

 

 

  

  

      

Page 10 

  
  
 

         
  

     

  

      

  

	 	b)	 Attending for an independent medical examination if required; and 

 

	 	c)	 Your co-operation with any reasonable request of the Company in relation to a
graduated return to work on suitable duties. 

 Compassionate Leave 

You will be entitled to three days’ paid leave payable at your Base Annualised Salary for each occasion when a member of your immediate family or household: 

 

	a)	 contracts or develops a personal illness that poses a serious threat to their life; or 

 

	b)	 sustains a personal injury that poses a serious threat to their life; or 

 

	c)	 dies. 

 Jury Service Leave 
 In the event you are required to attend for Jury Service, you will be paid your Base Annualised Salary less the
total of your jury service pay for the first 10 days of your absence. 
 Parental Leave 

Parental Leave is governed by the Fair Work Act 2009 ( Cth) and the Paid Parental Leave Act 2010 ( Cth), and includes adoption leave, maternity leave and paternity
leave. The Company’s parental leave policy, as amended from time to time, also applies. 
 Public Holidays 

Public Holidays as provided for in relevant legislation and gazetted for the coal industry and local government area will be observed, subject to your agreement to work
on these days if reasonably required to fulfil the requirements of your role. 
 VARIATION TO CONTRACT 

 
 This Contract may only be varied with the agreement of both you
and the Company in writing, subject to the prior approval of the Compensation Committee. 

  

 

     

 

  

 

 

  

  

      

Page 11 

  
  
 

         
  

     

  

      

  

 ENTIRE AGREEMENT 

 
 The terms and conditions of your employment contained in this
Contract represent the entire agreement for employment between the Company and you. 
 Thank you for considering our offer of employment and I look forward to working
with you at Peabody. 
  

					
	        /s/ Darren
Yeates                                        
        	 		  	DATE:        21 October 2020                    
	DARREN YEATES	 		  	
			
		 		  	
	PEABODY ENERGY AUSTRALIA COAL PTY LTD	 	        	  	DATE:        22 October 2020                    
			
		 		  	
	BY:        /s/ Ferdinand
Kruger                                        
    	 		  	
			
		 		  	
	TITLE:  Vice President, Operations - HR                    	 		  	

  

 

     

 

  

  

      

Page 12

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00315-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00315-of-00352.parquet"}]]